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ABSTRACT
There is little information on how the duration of overweight or obesity during life affects the risk for CKD. To
investigate whether prolonged exposure to overweight during adult life increases the risk of later CKD in a
cumulative manner, we analyzed data from the Medical Research Council National Survey of Health and
Development, a socially stratiﬁed sample of 5362 singleton children born in 1 week inMarch 1946 in England,
Scotland, andWales. Multiple imputation expanded the analysis sample from the initial 1794 participants with
complete data to 4584. This study collected self-reported bodymass index (BMI) at ages 20 and 26 years and
measured BMI at ages 36, 43, 53, and 60–64 years. The outcome of interest was CKD at age 60–64 years,
suggested by estimated GFR (eGFR),60ml/min per 1.73m2 and/or urine albumin-to-creatinine ratio (UACR)
$3.5 mg/mmol. In analyses adjusted for childhood and adulthood social class, ﬁrst becoming overweight at
younger ages was associatedwith higher odds of developing CKD by age 60–64 years. Compared with those
whoﬁrst becameoverweight at age60–64 yearsornever becameoverweight, thoseﬁrst overweight at age26
or 36 years hadapproximately double theoddsofdevelopingCKD.The strengthof this associationdecreased
with increasingagewhenﬁrstoverweight (P for trend,0.001). Theseassociationswereconsistent for creatinine-
based eGFR, cystatin C–based eGFR, and UACR. Taken together, these results suggest that preventing over-
weight in early adulthood may have a considerable effect on the prevalence of CKD in the population.
J Am Soc Nephrol 24: 813–821, 2013. doi: 10.1681/ASN.2012070675
Over recent decades, the prevalence of obesity has
increased dramatically in many parts of the world.1
The increasing recognition of kidney disease as a
cardiovascular risk factor,2 together with globally
increasing cardiovascular mortality,3 has led to a
growing interest in the relationship between obesity
and kidney disease, although the number of pub-
lished analyses remains limited. A recent systematic
review and meta-analysis4 concluded that adult
obesity increases the risk for kidney disease—
deﬁned by the authors as CKD, ESRD, kidney
stones, kidney cancer, or renal cell cancer—in the
general adult population. Obesity was found to
increase the risk of kidney disease by 40% (95%
conﬁdence interval [CI], 30%–50%) for adult
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overweight (25 # body mass index (BMI) , 30 kg/m2) and
83% (95% CI, 57%–113%) for adult obesity (BMI$ 30 kg/m2)
relative to normal weight (18.5, BMI, 25 kg/m2). However,
information on the prospective association between adult BMI
and CKD is very limited; among the reviewed studies, only
three cohort studies investigated the role of prior BMI in
CKD incidence. Previous cohort studies of obesity and kidney
disease have restricted their analysis to a single observation of
obesity, with the exception of Hsu et al.,5 who conducted a
subanalysis on people with more than one BMI measurement.
There is thus little information on how life course exposure to
obesity affects kidney disease risk.
The Medical Research Council National Survey of Health
and Development (NSHD) provides a unique opportunity to
explore how obesity throughout adult life affects kidney
function in a prospective cohort representative of the general
United Kingdom population. In addition to measurements of
urine albumin and creatinine and serum creatinine, this study
also measured serum cystatin C, which has been suggested as a
superior marker of kidney function.6
The aim of this paper is to investigate whether the data from
this study support the hypothesis that prolonged exposure to
overweight in adulthood, deﬁned in terms of BMI, increases
the risk of later CKD in a cumulativemanner. Furthermore, we
aim to investigate the extent to which any association between
adulthood overweight and CKD is mediated by diabetes and
hypertension and whether data support a similar association
with central adiposity.
RESULTS
BMIdatawere available at one ormore timepoints between age
20 and 60–64 years for 4463 study participants (83.2% of the
initial NSHD sample). BMI and the prevalence of overweight
increased during adulthood so that by age 60–64 years, 74.6%
of men and 67.3% of women were overweight (Supplemental
Figure 1). Themean BMI at age 60–64 years was higher among
men and women who became overweight earlier (Figure 1).
An individual’s BMI at age 60–64 years thus reﬂected the
length of time spent overweight. Age at ﬁrst overweight was
also strongly associated with waist-to-hip ratio at age 60–64
years (P,0.001 for trend). The mean sex-adjusted waist-to-
hip ratio was 7.6% (95% CI, 6.7 to 8.5) greater in study mem-
bers who became overweight at age 26 years than in those who
had not become overweight by age 60–64 years. Approxi-
mately 40% of men and women were from a non–manual-
labor social class during childhood, and approximately 80% of
men andwomenwere in such a class in adulthood. BMI at ages
26, 36, 43, 53, and 60–64 years was inversely associated with
both childhood and adulthood social class (all P,0.001). Sex-
adjusted BMI at age 60–64 years was 1.3 kg/m2 (95% CI, 0.8 to
1.9 kg/m2) greater in study members of manual-labor social
class in adulthood relative to those of non–manual-labor class.
More than 6% of study members were in the increased or high
midlife systolic BP latent trajectory. By age 60–64 years, 7% of
study members reported being diabetic, 5% were receiving
diabetes medication, and 30%were taking hypertension med-
ication. Mean hemoglobin A1c 6 SD was 5.8%60.7%, and
mean systolic BP was 134618 mmHg.
Serum creatinine data were available for 1855 study
participants: 20 (2.2%) men and 22 (2.3%) women had
creatinine-based eGFR , 60 ml/min per 1.73 m2 (P=0.83 for
sex difference). Serum cystatin C data were available for 2052
study participants, with 12 (1.2%)men and 35 (3.3%) women
having cystatin C–based eGFR , 60 ml/min per 1.73 m2
(P=0.001). Urinary albumin-to-creatinine ratio (UACR)
could be calculated for 2173 study participants: 40 (3.8%)
men and 22 (1.9%) women had UACR $ 3.5 mg/mmol
(P=0.01). The composite CKD measure was available for
1827 study participants, of whom 57 (6.3%) men and 51
(5.5%) women had CKD (P=0.44).
The subset of study participants with complete data are
likely to be a more health-conscious subgroup who have
adhered to follow-up for .60 years and thus are potentially
unrepresentative of the cohort as a whole. An analysis of only
complete cases may therefore provide biased results. We used
multiple imputation7,8 to explore the robustness of the com-
plete case results to this potential bias. The prevalence of re-
duced kidney function in the imputed data sets was generally
increased slightly relative to that in the original data. For ex-
ample, the prevalence of CKD by the composite measure was
increased to 7.9% in men and 8.4% in women.
Main Analyses
Because few study participants with reduced kidney function
had never become overweight, we combined the “ﬁrst over-
weight at age 60–64 years” and “never overweight” categories
for the purpose of the analysis.
For all four measures of kidney function, becoming over-
weight earlier was associated with increased odds of reduced
kidney function in the multiple imputation (MI) analysis (P for
trends , 0.001 to 0.05) (Tables 1–3). These trends remained
after adjustment for confounding by childhood and adulthood
socioeconomic position (P for trends, 0.001 to 0.06). Becom-
ing overweight at age 26 or 36 years was, relative to becoming
overweight at age 60–64 years or never becoming overweight,
associatedwith an approximately 2.1-fold increase in the odds of
reduced kidney function when creatinine-based eGFR was used
(Table 1), a 2.8-fold increase when cystatin C–based eGFR was
used (Table 1), and a 2.1-fold increase when the composite CKD
measure was used (Table 3). Evidence of an association between
becoming overweight at age 26 or 36 years andUACRwas some-
what weaker (Table 2). These associations showed only minor
attenuation after adjustment for childhood and adulthood so-
cioeconomic position.
Supplementary Analyses
In the corresponding complete case analyses, the evidence for
an association between earlier overweight and reduced kidney
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functionwas similarly strong (P for trends after adjustment for
childhood and adulthood socioeconomic position, 0.001 to
0.05) (Supplemental Tables 1–3). However, some of the in-
dividual odds ratios (ORs) associated with becoming over-
weight in early adulthood were greater in magnitude.
When we excluded individuals who did not remain over-
weight after they ﬁrst became overweight, the evidence for
associations between early overweight and reduced kidney
functionwas strengthened slightly in the complete case analysis
(it is not possible to perform this sensitivity analysis usingMI).
After adjustment for confoundingbychildhood and adulthood
socioeconomic position, the P values for trends varied be-
tween ,0.001 and 0.03 (results not shown).
The associations between overweight at each age and the
four indicators of reduced kidney function in the MI analysis
are shown in Supplemental Tables 4–6. Relative to not being
overweight at that age, being overweight at all ages from 36
years onward was associated with at least a 1.6-fold increase
in the odds of reduced kidney function, assessed using
creatinine-based eGFR. When we considered cystatin
C–based eGFR, overweight at all ages from 26 years onward
was associated with reduced kidney function, peaking at an
OR of 2.35 at age 36 years. Only overweight at age 36 years
was found to be associated with reduced kidney function
using UACR (OR, 1.67), with current overweight particularly
weakly associated (OR, 1.07). When we considered the com-
posite measure, overweight at all from age 26 years onward
was associated with CKD, peaking at an OR of 1.92 at age 36
years. These associations were only slightly attenuated upon
adjustment for childhood and adulthood socioeconomic
position.
In the corresponding complete case
analyses, the strongest associations were
seen at the same ages but the strength of the
associations was generally greater (Supple-
mental Tables 7–9).
The association between age at ﬁrst
overweight and kidney function at age
60–64 years was mediated to a similar ex-
tent by both diabetes and hypertension. In
the MI analysis, the minimally adjusted
ORs of 2.05 and 2.09 at ages 26 and 36 years
for the composite CKD measure (P for
overall trend , 0.001) were attenuated to
1.69 and 1.78 (P=0.003) after adjustment
for diabetes alone, to 1.66 and 1.76
(P=0.003) after adjustment for hyperten-
sion alone, and to 1.46 and 1.59 (P=0.03)
after adjustment for both diabetes and hy-
pertension (results not shown). There was
no evidence of statistical interaction be-
tween either diabetes or hypertension and
age at ﬁrst overweight.
Waist-to-hip ratio at all three ages (43,
53, and 60–64 years) was found to be asso-
ciated with kidney function at age 60–64 years, although the
cross-sectional association was markedly weaker. A 0.05-unit
increase in waist-to-hip ratio corresponded to ORs of 1.24
(95% CI, 1.10 to 1.40), 1.21 (95% CI, 1.07 to 1.35), and
1.12 (95% CI, 1.01 to 1.25) at ages 43, 53, and 60–64 years,
respectively, whenwe considered the composite CKDmeasure
in the MI analysis (results not shown). Adding waist-to-hip
ratio at age 43 or 53 years to the models for age at ﬁrst over-
weight attenuated the associations to amoderate degree. In the
MI analysis, the minimally adjusted ORs of 2.05 and 2.09 at
ages 26 and 36 years for the composite CKD measure (P for
overall trend , 0.001) were attenuated to 1.70 and 1.78
(P=0.004) after adjustment for waist-to-hip ratio at age 43
years and to 1.73 and 1.80 (P=0.003) after adjustment for
waist-to-hip ratio at age 53 (results not shown).
The population attributable fraction for the composite
CKDmeasurewas calculated as 29.0% for the study sample and
35.9% for the current United States population. It should be
noted that this comparison involves observed levels of over-
weight versus becoming overweight at age 60–64 years or never
becoming overweight because these categories were combined
in the analysis.
Finally, an additional sensitivity analysis looked at the associ-
ation between age atﬁrst overweight and reduced kidney function
using the original age at ﬁrst overweight categories (i.e., not com-
bining “ﬁrst overweight at age 60–64 years” and “never over-
weight”). The effect of early overweight was somewhat stronger
relative to “never overweight” than relative to “ﬁrst overweight at
age 60–64 years or never overweight,” but the precisionwasmark-
edly reduced (results not shown). The overall tests for trend were
very similar to those presented in the main analysis above.
Figure 1. Mean body mass index (BMI) was higher throughout adulthood in men and
women who became overweight at earlier ages. Shaded areas are 95% conﬁdence
intervals. Modiﬁed from reference 32, with permission.
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DISCUSSION
In a large, population-based, prospective study, we found
overweight beginning early in adulthood (by ages 26 or 36
years) to be strongly associated with reduced renal function at
age 60–64 years. To our knowledge we are the ﬁrst to report
how exposure to overweight across adulthood may affect kid-
ney disease risk.
Waist-to-hip ratio in adulthood, particularly at ages 43 and
53 years, was found to be associatedwith kidney function at age
60–64 years. This reinforces the observed associations with
overweight, implying they are not just due to a peculiarity of
BMI (e.g., “overweight” in early adulthood really signifying
high lean body mass that tracks through adulthood, leading
to raised creatinine levels). In addition, we found diabetes and
hypertension to both be moderate mediators of the associa-
tion between age at overweight and kidney function.
We estimated that 36% of CKD cases at age 60–64 years in
the current United States population could be avoided if no-
body became overweight until at least age 60–64 years, assuming
the same associations as in the analysis sample. This emphasizes
the importance of obesity as a risk factor for CKD.
Table 1. ORs for eGFR , 60 ml/min per 1.73 m2 by age when ﬁrst overweight in the MI analysis (n=4584)
Age when First
Overweight (yr)
Percentagea among Total
First Overweight
at This Age
Percentagea of Those First
Overweight at This Age with
eGFR , 60 ml/min per 1.73 m2
Model 1 Model 2
OR (95% CI)
P Value
for Trend
OR (95% CI)
P Value
for Trend
Creatinine-based eGFR
26 21.0 4.7 2.08 (1.10–3.94) 0.008 1.99 (1.04–3.80) 0.01
36 18.8 5.0 2.16 (1.12–4.17) 2.10 (1.09–4.07)
43 14.3 3.6 1.51 (0.71–3.21) 1.51 (0.71–3.19)
53 16.9 3.0 1.27 (0.59–2.73) 1.27 (0.59–2.73)
60–64 or never 29.0 2.4 1.00 1.00
Cystatin-based eGFR
26 21.0 3.7 2.78 (1.30–5.93) 0.002 2.48 (1.16–5.29) 0.005
36 18.8 3.6 2.74 (1.30–5.78) 2.54 (1.21–5.34)
43 14.3 3.0 1.86 (0.81–4.26) 1.81 (0.79–4.16)
53 16.9 2.2 1.28 (0.53–3.07) 1.27 (0.53–3.02)
60–64 or never 29.0 1.8 1.00 1.00
Model 1: Adjusted for age at examination and sex. Model 2: Additionally adjusted for childhood and adulthood socioeconomic position.
aAverage across all 50 imputed data sets.
Table 2. ORs for UACR $ 3.5 mg/mmol by age when ﬁrst overweight in the MI analysis (n=4584)
Age When First
Overweight (yr)
Percentagea of Total
First Overweight
at This Age
Percentagea of Those First
Overweight at This Age with
UACR ‡ 3.5 mg/mmol
Model 1 Model 2
OR (95% CI)
P Value
for Trend
OR (95% CI)
P Value
for Trend
26 21.0 3.8 1.75 (0.93–3.28) 0.05 1.72 (0.91–3.27) 0.06
36 18.8 3.7 1.71 (0.85–3.42) 1.68 (0.83–3.36)
43 14.3 2.3 1.05 (0.44–2.50) 1.04 (0.44–2.46)
53 16.9 2.5 1.18 (0.57–2.45) 1.17 (0.56–2.42)
60–64or never 29.0 2.1 1.00 1.00
Model 1: Adjusted for age at examination and sex. Model 2: Additionally adjusted for childhood and adulthood socioeconomic position.
aAverage across all 50 imputed data sets.
Table 3. ORs for composite CKD measure by age when ﬁrst overweight in the MI analysis (n=4584)
Age When First
Overweight (yr)
Percentagea of Total
First Overweight
at This Age
Percentagea of Those First
Overweight at This Age with
Composite CKD Measure
Model 1 Model 2
OR (95% CI)
P Value
for Trend
OR (95% CI)
P Value
for Trend
26 21.0 10.6 2.05 (1.37–3.07) ,0.001 1.94 (1.28–2.93) ,0.001
36 18.8 10.9 2.09 (1.32–3.28) 2.01 (1.27–3.17)
43 14.3 7.6 1.35 (0.80–2.27) 1.33 (0.79–2.24)
53 16.9 6.6 1.15 (0.71–1.87) 1.14 (0.71–1.86)
60–64 or never 29.0 5.8 1.00 1.00
Model 1: Adjusted for age at examination and sex. Model 2: Additionally adjusted for childhood and adulthood socioeconomic position.
aAverage across all 50 imputed data sets.
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Because so few individuals returned to normal weight after
becoming overweight, it was not possible to separate the effects
of the timing of becoming overweight and duration of over-
weight. Alternative cohorts containing more individuals who
return to normalweightwould be required to disentangle these
potential life course models for the effect of overweight.
Overweight and obesity have been shown in previous
observational studies to be associated with various types of
kidney disease. The associations observed in the present study
are stronger than those in a similar meta-analysis of three
cohort studies with CKD as an outcome4 and are closer to the
estimates of the association between obesity and renal disease
of all types, particularly ESRD.4 Fox et al.9 studied “new-onset
kidney disease” (deﬁned as GFR #64 ml/min per 1.73 m2 in
men or#59 ml/min per 1.73 m2 in women) in 2585 men and
women followed up for a mean of 18.5 years in the Framing-
ham Offspring Study. Baseline BMI was found to increase the
odds of kidney disease by 23% per SD unit (OR, 1.23; 95% CI,
1.08 to 1.41). Gelber et al.10 evaluated the association between
BMI and CKD (deﬁned as estimated GFR , 60 ml/min per
1.73 m2) in a cohort of 11,104 initially healthy men during an
average follow-up of 14 years. They found higher baseline BMI
to be consistently associated with CKD, with those in the high-
est BMI quintile having an OR of 1.45 (95% CI, 1.19 to 1.76)
relative to those in the lowest quintile. However, in 9082
United States adults from the Second National Health and
Nutrition Examination Survey(NHANES II), Stengel et al.11
found an increased risk of CKD (deﬁned as receipt of treat-
ment for ESRD or death related to CKD) only for those with
baseline BMI$35 kg/m2 (morbid obesity). Later research has
suggested that BMI is a suboptimal measure of risk and that
other measures of central obesity, for example waist-to-hip
ratio, should be used.12 Our study is in line with these earlier
studies but adds important nuances: namely the importance of
quantifying when the person became overweight or the dura-
tion of overweight.
Themagnitude and size of the associationswe found suggest
that preventingoverweight before age 40 years could reduce the
risk of later risk of CKD considerably. OnceCKD is present, no
other known treatment target prevents progression of CKD to
the same degree. Our ﬁndings suggest that interventions to
reduce overweight at any age in adulthood may reduce the
burden of later CKD, but to maximize the effect of any
interventions they should focus on reducing the prevalence of
overweight in early adulthood. Indeed, because of the ac-
knowledged tracking ofBMI fromchildhood into adulthood,13
it may be necessary to target interventions earlier still.
The mechanisms relating BMI to CKD are not well un-
derstood. Our ﬁndings may be due to a series of mechanisms,
all initiated by high BMI, including (1) the inﬂuence of BMI on
BP;14 (2) initial hyperﬁltration, development of albuminuria,
and subsequent decline in eGFR, as suggested by animal stud-
ies;15,16 (3) development of diabetes;17 and (4) inﬂuences on
the immune system contributing to inﬂammation that are not,
as yet, well understood.18 The data do not allow the sequence
of events to be disentangled (i.e., whether albuminuria or in-
ﬂammation preceded development of low eGFR). However,
the size and direction of the associations, in particular the
peaking of the associations at younger ages, suggest a “lag”
between becoming overweight and subsequently developing
CKD. In line with animal models, a series of cross-sectional
studies have found increased eGFR and increased albuminuria
to be positively associated with concurrent BMI.19–21
A limitation of this study is the low power due to the low
prevalence of reduced kidney function in the cohort, although
prevalencewas increased slightly by the use of anMI approach.
However, the patterns of associations within each measure of
kidney function and the similarity in ﬁndings across the three
different measures of kidney function (and a composite
measure) suggest robustness to our ﬁndings. Results from
the sensitivity analysis inwhich individualswhodidnot remain
overweight once they had ﬁrst become overweight were
excluded strengthen the evidence for the association between
early overweight and reduced kidney function at age 60–64
years.
In addition, the lack of study participants with reduced
kidney functionwho had never become overweightmeant that
we had to combine the “ﬁrst overweight at age 60–64 years”
and “never overweight” categories for the purpose of the anal-
ysis. Using only “never overweight” study members as the
baseline group increased the magnitude of all the associations
at the expense of precision. Our results thus probably under-
estimated the real effects of interest.
We did not further divide overweight into overweight (25#
BMI, 30 kg/m2) and obesity (BMI$ 30 kg/m2) because the
prevalence of obesity was low in early adulthood in this cohort
(3% at age 26 and 5% at age 36 years); this, coupled with the
low prevalence of CKD, would have given us very low statis-
tical power to detect any associations. In other settings, the
overweight proﬁle would probably be different from that
of this cohort, so a focus on obesity may well be more
appropriate.
The lackof repeatedmeasures of kidney functionmeant that
we were unable to ascertain CKD using the recommended
deﬁnitionof reduced kidney function for at least 3months.22,23
This is likely to introduce nondifferential misclassiﬁcation,
again meaning that the true association is even stronger than
described here.
Confounding by childhood and adulthood socioeconomic
position did not explain the observed associations, although
residual confounding is a possibility. Residual mediation by
hypertension may also be possible. Several previous studies
have reported a stronger association between obesity and
kidney disease in women than in men.4,24 Although no evi-
dence of sex differences was found in this study, our lack of
statistical power to detect these interactions means we cannot
rule out such differences.
A strength of this study is that it has repeated measures of
BMI at regular intervals throughout adulthood, with heights
and weights measured using standardized protocols at the
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majority of these ages, and sufﬁciently detailed information
about socioeconomic position. Additionally, the availability of
three different measures of kidney function allows a more
thorough analysis. The cohort members remaining in the
NSHD have been found to be broadly representative of native-
bornadults living inEngland,Scotland, andWales at the timeof
data collection at age 5325 and at age 60–64 years.26 Hence, we
are conﬁdent that our analysis sample retains the representa-
tives of the study population as a whole. Use of MI allowed us
to investigate the role of selection bias on the results, with the
MI analyses giving results similar to those of the complete case
analyses overall. The NSHD study population is, however, all
white, and therefore our ﬁndings cannot be extrapolated to the
nonwhite British population.
In conclusion, we found being overweight in early adult-
hood to be strongly associatedwith reduced kidney function in
later life. Although we were unable to disentangle precisely
whether itwas the timingofoverweightonsetor thedurationof
overweight thatwas driving this association, either explanation
suggests that preventing overweight in early adulthood may
have a considerable effect on the prevalence of CKD in the
population. Indeed, doing soappears tohavea largereffect than
any treatment for CKD known to date. The recent epidemic of
obesity, resulting in overweight beginning at earlier ages (from
early adult life and more recently from adolescence and
childhood), is leading to a substantial increase in over-
weight/obesity of long duration, which could have important
consequences for renal disease, as well as for cardiovascular
disease.27
CONCISE METHODS
Participants
The Medical Research Council NSHD is a socially stratiﬁed sample
of 5362 singleton children born in 1 week in March 1946 in England,
Scotland, and Wales. Medical and social data have been collected
23 times by home visits, medical examinations, and postal
questionnaires.28
Measures
Adult heights andweights weremeasured at ages 36, 43, 53, and 60–64
years and were self-reported at ages 20 and 26 years. BMI, deﬁned as
weight (kg)/height (m2), was calculated at each age. A binary variable
indicating overweight was calculated at each age, using the standard
cut point of 25 kg/m2.
The main exposure of interest was the age at which a study
participant ﬁrst became overweight (26, 36, 43, 53, or 60–64 years or
never). This was derived assuming that once an individual became
overweight he or she remained overweight. Overweight at each sep-
arate age (20, 26, 36, 43, 53, and 60–64 years) was considered as a
secondary analysis.
Four different indicators of reduced renal function at age 60–64
years were used: (1) creatinine-based eGFR, 60ml/min per 1.73m2;
(2) cystatin C–based eGFR, 60ml/min per 1.73 m2 (both calculated
using the Chronic Kidney Disease–Epidemiology Collaboration for-
mulae29,30); (3) UACR $ 3.5 mg/mmol; and (4) a composite CKD
measure indicating whether any one or more of the previous three
indicators were present.
Childhood socioeconomic position (manual labor/non–manual-
labor) and adulthood socioeconomic position (manual labor/non–
manual labor) were considered as potential confounders.
Diabetes (self-reported physician-diagnoseddiabetes by age 60–64
years, receiving diabetes medication at age 60–64 years, hemoglobin
A1c level at age 60–64 years) and hypertension (previously derived
systolic BP latent trajectory between ages 36 and 53 years,31 receiving
BP medication at age 60–64 years, measured systolic BP at age 60–64
years) were considered as mediating factors.
Some previous studies have indicated that central obesity is a
stronger predictor of CKD than is BMI.4 A ﬁnal analysis thus examined
whether adulthood waist-to-hip ratio was associated with kidney func-
tion at age 60–64 years in the sameway as adulthood overweight.Waist-
to-hip ratios at ages 43, 53, and 60–64 years were derived using repeated
measures of waist and hip circumferences.
Statistical Analyses
Main Analyses
Each kidney function outcome was related to age at ﬁrst overweight
using logistic regression. Models were minimally adjusted for sex and
age (model 1), then additionally adjusted for childhood and adult-
hood SEP (model 2). A similar approach has previously been used to
assess the relationship between patterns of overweight during adult-
hood and BP at age 53 years in the NSHD.32
To investigate the potential bias caused bymissing data, we used an
MI approach.7,8 See Supplemental Material for full details.
Supplementary Analyses
The analysis relating each kidney function outcome to age at ﬁrst
overweight outlined abovewas repeated using complete cases only as a
comparison with the MI results. A sensitivity analysis was conducted
inwhichany individualswhodidnot remainoverweight once theyhad
ﬁrst become overweight were excluded.
We investigated the associations between each kidney function
outcome and overweight status at each age with logistic regression,
using both an MI approach and a complete case analysis for
comparison.
The extent towhich the association between age at ﬁrst overweight
and kidney function at age 60–64 years was mediated by diabetes and
hypertension was examined by adding each of these to the models for
age at ﬁrst overweight and examining the extent to which the effect
estimates were attenuated.
Associations between waist-to-hip ratio at each age and kidney
function at age 60–64 years were examined in the same way as over-
weight at each age. Waist-to-hip ratio at ages 43 and 53 years were
then added in turn to the models for age at ﬁrst overweight to exam-
ine whether the association remained once waist-to-hip ratio was
taken into account.
Finally, population attributable fractions for the composite CKD
measure were calculated using theMImodel adjusted for age, sex, and
childhood and adulthood socioeconomic position.33 This represents
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the proportion of CKD cases occurring in the total population that
would have been avoided if nobody had become overweight. Popu-
lation attributable fractions were calculated using the study sample
and for the current United States population. For the latter, over-
weight prevalences at the appropriate ages (26, 36, 43, 53, and 60–64
years) were derived by interpolating the NHANES 2009–2010 esti-
mates of Flegal et al.,34 with the proportion of people becoming over-
weight in each interval calculated as the difference between the two
consecutive prevalences (e.g., the proportion of people becoming
overweight between ages 26 and 36 years was the difference between
the overweight prevalence at age 36 and the overweight prevalence at
age 26 years).
In none of the models was there any evidence of interactions
with sex, so combined male and female models are presented
throughout.
The analysis was performed using Stata software, version 12.35
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